We are thrilled to announce that through our strategic supply partnership with Prima BioMed, Prima’s first-in-class immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi’s state-of-the-art cGMP facility in China, has now been dosed in a Phase IIb clinical trial in Belgium.  This is the first time a biologic manufactured in China has been released for use in a clinical trial within countries in the EU.  This also marks the first patient being dosed in AIPAC (Active Immunotherapy PAClitaxel), Prima’s Phase IIb clinical trial in metastatic breast cancer. WuXi is supplying IMP321 to Prima’s AIPAC trial, which is being conducted in Europe, as well as to its TACTI-Mel Phase I melanoma trial currently recruiting in Australia.

With the start of this exciting clinical trial for IMP321, in addition to recent Clinical Trial Application filings and approvals for other product candidates of WuXi partners, WuXi Biologics is rapidly becoming a significant contributor to the expedited development of innovative biologics in the EU.


Related Articles:

  1. WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic
  2. Congratulations to TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S FDA